{
  "id": 16626294,
  "title": "Lower Metastasis Risk in Very High-Risk Prostate Cancer With Intensified Treatment",
  "url": "https://urgent.news/2026/10/26/lower-metastasis-risk-in-very-high-risk-prostate-cancer-with",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T15:34:29.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/esmo/123578"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Men with very high-risk prostate cancer had a significantly lower risk of metastasis when they received darolutamide (Nubeqa) in addition to androgen deprivation therapy (ADT) and radiation therapy (RT), a randomized trial showed...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}